Shelly Hod Moyal

Board Director at Antidote Health

Shelly Hod Moyal has a strong background in venture capital and investment. In 2013, they co-founded iAngels, a women-led venture capital firm and investment platform. As a Founding Partner and Co-CEO of iAngels, they offer accredited investors worldwide access to tech startups and scaleup investment opportunities from Israel. Shelly is also a General Partner in the iNgenuity Fund, an institutional fund backed by the European Investment Fund.

Shelly has also held various board positions in different companies. In 2022, they became a Board Director at Seed-X, Vyzer, and Guardz. Shelly has been a Board Observer at H2Pro, Ltd. since 2019. In addition, Shelly serves as a Board Director for binah.ai, Innovopro, Antidote Health, Urecsys, and Medorion.

Their expertise and experience in the field make their a valuable asset in guiding and advising these companies in their strategic decision-making processes.

Shelly Hod Moyal completed their Master of Business Administration (MBA) at Northwestern University - Kellogg School of Management from 2013 to 2015. Prior to that, they earned a Bachelor's degree in Economics from Hunter College, where they studied from 2005 to 2007.

Links

Timeline

  • Board Director

    February, 2021 - present